The aim of the study was to evaluate the long-term response to antiretroviral treatment (ART) based on atazanavir/ritonavir (ATZ/r)-, darunavir/ritonavir (DRV/r)-, and lopinavir/ritonavir (LPV/r)-containing regimens.
Introduction
The new global 90-90-90 World Health Organization (WHO) targets call for 90% of all people with HIV infection to be diagnosed, 90% of people with an HIV diagnosis to be treated, and 90% of treated subjects to have virological suppression by 2020 [1] . Standard antiretroviral treatment (ART) is still based on a combination of at least three antiretroviral drugs [2] [3] [4] , it is generally expensive, and there are still many limitations to its use, especially in developing countries.
Consistent with ART optimizing principles, availability of fixed-dose combinations, tolerability, and the risk of resistance mutations, recent WHO recommendations for the limited resource setting include the use of nonnucleoside reverse transcriptase inhibitors and integrase strand-transfer inhibitors in first-line ART, and darunavir/ritonavir (DRV/r), lopinavir/ritonavir (LPV/r), and atazanavir/ritonavir (ATZ/r) as alternative drugs in second and third ART regimens [1] . Nevertheless, these drugs have different profiles of efficacy, safety, and tolerability [5] [6] [7] [8] .
Because the effectiveness of therapy in daily clinical practice usually differs from what is observed in clinical trials [9, 10] , it is important to analyse the experience with the use of DRV/r, ATZ/r, and LPV/r in unselected HIV-infected patients. This study aimed to evaluate the long-term effectiveness of DRV/r-, ATZ/r-, and LPV/rcontaining regimens initiated at various stages during participants' ART history and the factors associated with virological failure (VF), treatment discontinuation, and CD4 cell count recovery in a large European cohort of HIV-1-infected patients.
Methods

Study population and data collection
The EuroSIDA study is a prospective, observational cohort study of >22 000 HIV-positive subjects in 105 centres in 35 European countries, Israel, and Argentina, which has been described in detail previously [11] [12] [13] [14] . The study population of the present analysis included all EuroSIDA-enrolled patients initiating an ATZ/r-, DRV/r-, or LPV/r-containing regimen between 1 January 2000 and 30 June 2013 who also had at least one additional clinical visit. Patients were included if they satisfied the inclusion criteria for one of the following groups: (1) ART na€ ıve, i.e. previously untreated subjects at the time of boosted protease inhibitor (PI/r) initiation; (2) ART switching, i.e. ART-experienced individuals initiating the new PI/r with a VL ≤ 500 HIV-1 RNA copies/mL; and (3) ART salvage, i.e. ART-experienced patients initiating the new PI/r with a VL > 500 copies/ mL, including patients who were on a voluntary ART interruption. Prior exposure to PI/r was allowed. Data were collected at the date of DRV/r, ATZ/r or LPV/r initiation (baseline) and during the follow-up period, according to the EuroSIDA study protocol. Data collected for this analysis included demographic characteristics (age, gender, ethnicity and route of HIV infection transmission), AIDS stage at the time of PI/r initiation, hepatitis C and B virus (HCV/HBV) coinfections, HIV-1 RNA levels, CD4 cell counts, CD4 count nadir at baseline, number of previous failures of treatment with specific drug classes, previous exposure to PI, nucleos(t) ide reverse transcriptase inhibitor (NRTI) backbones included in the PI/r regimen, and genotypic test results performed before DRV/r, ATZ/r or LPV/r initiation (when available).
The primary endpoint of this analysis was the median time to VF after DRV/r, ATZ/r or LPV/r initiation. VF was defined as two consecutive VLs ≥ 200 copies/mL at 24 weeks or at any time after achieving a VL ≤ 50 copies/ mL. The date of the first VL ≥ 200 copies/mL was used to define the time at which VF had occurred. The secondary endpoints were time to the composite endpoint of VF or PI/r discontinuation, and time to achieve a gain of CD4 count ≥ 200 cells/lL above the baseline level while the person remained with a VL ≤ 200 copies/mL.
Prior approval was given by the Ethics Committee of each participating centre for the study, which is being carried out according to the stipulations of the Declaration of Helsinki (Seoul, 2008). All patients gave their written informed consent prior to participation.
Statistical analysis
For descriptive purposes, Europe was divided into six regions: north (Denmark, the UK, Ireland, the Netherlands, Norway, Finland and Sweden); east (Belarus, Estonia, Latvia, Lithuania, Russia and Ukraine); west central (Austria, Belgium, France, Germany, Luxembourg and Switzerland); east central (Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Serbia and Slovakia); and south (Greece, Italy, Spain, Portugal and Israel). Data for Argentina were analysed separately. Variables with a normal distribution were described as mean (standard deviation) and compared using the t-test. Median and interquartile range (IQR) were used to describe variables that did not follow a normal distribution, which were compared using a nonparametric test. Percentages were compared using the v 2 test or an exact binomial test when appropriate. Separate analyses were performed in the ART-na€ ıve group and each of the two ART-experienced groups. Kaplan-Meier analysis was used to determine the median time to VF and the proportion of patients who experienced VF up to 5 years from starting the PI/rbased regimen. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated and a proportional hazards Cox regression model was used to identify factors associated with each of the three considered outcomes. Multivariable models were fitted using 0.05 as the significance level in univariable analysis for a covariate to be included in the final multivariable model. The relationship between the final set of included covariates was checked and a variable was removed when collinearity was detected. Effectiveness was evaluated with an intention-to-treat (ITT) analysis ignoring treatment switches of PI/r (genuine ITT analysis). Sensitivity analyses were performed with any discontinuation of PI/r counted as failure [ITT: switching = failure (S = F)], counting as failures only discontinuations of PI/r because of toxicity [ITT: switch for toxicity = failure (T = F)], and with data censored at the date of PI/r discontinuation [on-treatment (OT) analysis]. In addition, in the pre-treated population subgroup that had initiated the new PI/r-containing regimen with VL > 500 copies/mL, sensitivity analyses were also performed on those subjects initiating PI/r after 2004 and with genotyping tests available.
Statistical analysis was performed using SAS version 9.3 (SAS Institute, Cary, NC).
Results
A total of 5678 of 18 913 HIV-infected individuals enrolled in the EuroSIDA study up to 30 September 2013 met the inclusion criteria for this analysis.
ART-na€ ıve subgroup
Of these 5678 patients, a total of 431 (8%) were ARTna€ ıve patients of whom 220 (51%) were receiving LPV/r, 119 (28%) were on ATZ/r, and 92 (21%) were on DRV/rbased regimens. The median (IQR) time of follow-up was 28 (11-57) months. Table 1 presents the baseline characteristics of this subgroup of patients. Median (IQR) CD4 cell counts and HIV VLs were 261 (164-352) cells/lL and 79 271 (780-8 415 274) copies/mL, respectively. Genotypic resistance tests before PI/r initiation were available for 111 (26%) subjects.
Of the 431 patients included, 79 (18%) experienced VF during the follow-up. Of the 184 (42.7%) subjects with the composite endpoint of VF or PI/r discontinuation, PI/r was discontinued in 148 (80.4%). In the genuine ITT analysis, the median time to VF was longer (log rank; P = 0.004) for patients who initiated DRV/ r-based treatment in comparison to those patients initiating ATZ/r or LPV/r (Fig. 1a) . Similarly, patients initiating DRV/r also had a longer median time to failure compared with those initiating ATZ/r or LPV/r in the ITT: S = F and ITT: T = F sensitivity analyses (Figs 1b and c), but not in the OT analysis (Supporting Information Fig. S1a) .
After adjustment for confounding variables, the multivariable Cox proportional hazard model showed no differences between DRV/r, ATZ/r and LPV/r in the ITT analysis and when we examined the composite endpoint of VF or PI/r discontinuation (Fig. 1d) . Nevertheless, patients with an AIDS diagnosis at the time of initiation of their first PI/r-based ART were significantly more likely to experience VF (HR 2.97; 95% CI 1.26-7.03; P = 0.01), and female gender (versus male: HR 2.08; 95% CI 1.20-3.63; P = 0.01) was associated with a higher risk in the ITT: S=F sensitivity analysis (Fig. S2) .
No differences were found with regard to the probability of a CD4 cell count increase of ≥200 cells/lL in the Cox proportional hazard model (Fig. 1d ) when comparing the three PI/r treatment groups.
ART-switching subgroup
A total of 2507 (44%) subjects had been switched to DRV/r, ATZ/r or LPV/r with an HIV VL ≤ 500 copies/mL. Of these, 1031 (41%) started an LPV/r-based, 824 (33%) started an ATZ/r-based, and 652 (26%) started a DRV/rbased regimen. The median (IQR) time of follow-up was 40 (17-68) months, and the median (IQR) CD4 cell count was 468 (317-652) cells/lL. The median (IQR) number of previous PIs previously experienced was 2 (1-3) and historical genotypic resistance tests before switching to PI/r were available for 1171 (47%) patients ( Table 2 ). The median (IQR) duration of continuous viral suppression prior to baseline was 56 (32-84) months.
Out of the 2507 patients included in this subgroup, 408 (16%) experienced VF during the follow-up. Of the 1278 (51.0%) subjects with the composite endpoint, PI/r was discontinued in 1042 (81.5%). In the ITT analysis, the median time to VF was longer (log rank; P < 0.0001) for patients who initiated a DRV-switch strategy ( Switching to LPV/r (HR 2.56; 95% CI 1.62, 4.05; P < 0.001) or ATZ/r (HR 1.98; 95% CI 1.27, 3.08; P < 0.001) was associated with a higher risk of VF in comparison to DRV/r in the multivariable Cox proportional hazard model according to the ITT analysis (Fig. 2d ). In addition, injecting drug use, higher HIV-1 RNA at baseline, black ethnicity, having historic genotyping tests available, and a higher number of prior failures on non-PI-based ART were independent predictors of an increased hazard of VF. The association with baseline VL was confirmed when it was explored using a categorical variable [RH 1.64 (95% CI 1.22, 2.21; P = 0.001) and RH 1.87 (95% CI 1.39, 2.53; P < 0.001) comparing the VL ≤ 50 copies/mL stratum with 51-200 and 201-500 copies/mL, respectively]. By contrast, younger age, a higher CD4 cell count at switching, and having initiated DRV/r, ATZ/r or LPV/r more recently were all associated with a lower hazard of VF (Fig. S4 ). The use of DRV/r, ATZ/r or LPV/r, however, was not found to be predictive of CD4 count response in the multivariable Cox proportional hazard model (Fig. 2d ).
ART-salvage subgroup
A total of 2740 (48%) patients began DRV/r, ATZ/r or LPV/r with HIV-1 RNA ≥ 500 copies/mL. Of these, 1893 (69%) started an LPV/r-based, 594 (22%) started an ATZ/ r-based, and 253 (9%) started a DRV/r-based regimen. Their median (IQR) time of follow-up was 35 (12-72) months. The median (IQR) CD4 cell count and HIV VL were 260 (156-380) cells/lL and 31 482 (501-7 943 282) copies/mL, respectively. The median (IQR) number of PIs previously experienced was 2 (1-3) and genotypic resistance tests were available for 1268 (46%) subjects (Table 2) .
Of the 2740 patients included, 942 (34%) experienced VF during the follow-up. Of the 1812 (66%) subjects with the composite endpoint, PI/r was discontinued in 1267 (70%). In the ITT analysis, the median time to VF was longer (log rank; P < 0.001) for patients who initiated DRV/r-based treatment as a salvage ART regimen (Fig. 3a) , with a risk of developing VF of 14.2% (95% CI 8.6, 19.9%) by 3 years, compared with patients who initiated ATZ/r (20.6%; 95% CI 17.1, 24.1%) or LPV/r (37.9%; The multivariable model included age, gender, mode of HIV transmission, hepatitis B and C virus coinfection status, AIDS diagnosis before baseline, CD4 count at baseline, CD4 count nadir, viral load at baseline, nucleoside pair included in regimen, calendar year of baseline, ethnicity, and whether at least one resistance test was available prior to baseline. All models were stratified by clinical site. ART, antiretroviral therapy; CI, confidence interval; VL, virological load; OT, on treatment; PI/r, ritonavir-boosted protease inhibitor; RH, relative hazard; Obs, observed. (17) 285 (28) 212 (26) <0.001
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95% CI 35.6, 40.2%). Similarly, patients initiating DRV/r also showed a longer time to failure compared with those initiating ATZ/r or LPV/r in sensitivity analyses (Fig. 3b,  c and Fig. S1c) , and in the analyses restricted to subjects with a pre-treatment genotype available (Fig. S5) or initiating boosted PI after 2004 (Fig. S6) . In addition, patients who initiated LPV/r (HR 1.61; 95% CI 1.02, 2.54; P = 0.040) had a higher risk of VF than those who initiated DRV/r in the multivariable Cox proportional hazard model (Fig. 3d) . Furthermore, having acquired HIV infection through heterosexual sex (compared with men who have sex with men), a higher HIV-1 RNA at salvage regimen initiation, and a higher number of prior failures to respond to PI/r-based ART were associated with increased risk of VF. By contrast, younger age, higher CD4 cell count at ART rescue, and having started DRV/r, ATZ/r or LPV/r in more recent years were associated with a lower hazard of VF (Fig. S7) .
When we examined the composite endpoint of VF or PI/r discontinuation, starting LPV/r-or ATZ/r-based regimens as salvage ART was associated with a higher risk [HR 3.12 (95% CI 2.28-4.28; P < 0.001) and HR 2.09 (95% CI 1.52-2.88; P < 0.001), respectively] than starting DRV/r in the ITT: S = F sensitivity analysis. Similar results were also observed in the ITT: T = F analysis (Fig. S7) .
The use of DRV/r, ATZ/r or LPV/r was not found to be predictive of CD4 count response in the multivariable Cox proportional hazard model (Fig. 3d) , although a higher CD4 nadir, a lower HIV RNA, and the availability of a genotyping test were all factors associated with a better chance of CD4 count recovery (Fig. S3) .
Discussion
In this analysis, when we examined endpoints that counted PI/r discontinuation as treatment failure, there was a clear superiority of DRV/r over LPV/r and ATZ/r. Indeed, although the risk of VF was similar for DRV/r, ATZ/r and LPV/r in ART-na€ ıve patients, the risk of PI/r discontinuation for any reason was lowest for DRV/r. In the treatment-experienced patients who initiated PI/r either as a result of a switching strategy with a suppressed VL or as a salvage treatment, the percentage of patients who experienced VF and the risk of VF or PI/r discontinuation were lower for DRV/r compared with both LPV/r and ATZ/r.
In ART-na€ ıve patients, the antiviral efficacy of ATZ/r has been shown to be similar to that of DRV/r and LPV/r in randomized studies [5, 15, 16] . However, ATZ/r shows The multivariable model included age, gender, mode of HIV transmission, hepatitis B and C virus coinfection status, AIDS diagnosis before baseline, CD4 count at baseline, CD4 count nadir, viral load at baseline, nucleoside pair included in regimen, calendar year of baseline, ethnicity, and whether at least one resistance test was available prior to baseline. All models were stratified by clinical site. ART, antiretroviral therapy; CI, confidence interval; VL, viral load; OT, on treatment; PI/r, ritonavir-boosted protease inhibitor; RH, relative hazard; Obs, observed.
higher rates of jaundice and hyperbilirrubinaemia than DRV/r and LPV/r [5, 16] , a worse lipid profile than DRV/r [15, 17] , albeit with less gastrointestinal toxicity, and a better lipid profile than LPV/r. 5 In addition, DRV/r is superior to LPV/r in virological response [18] , with a higher genetic barrier [6, 19] , higher efficacy in patients of different genders, ages, races and coinfection statuses [20] , and fewer discontinuations because of adverse events [6] . In our analysis, we found no significant differences in the risk of VF between the three drugs. It must be noted, however, that the number of VF events was especially small for DRV/r, so the analysis of the ARTna€ ıve population was probably underpowered. In contrast, and coinciding with the literature [6, 16] , we observed that the risk of PI/r discontinuation for any reason was > 2.5 times higher in patients who started LPV/ r-based ART than in those initiating a DRV/r-based ART, while no significant difference was observed when ATZ/r and DRV/r regimens were compared. In addition, the study design and limited number of ART-na€ ıve patients, including those with HIV VL > 100 000 copies/mL and low CD4 cell counts, might partly explain why prior AIDS diagnosis and female gender, but not the CD4 cell count and HIV RNA, were identified as predictive factors of virological response and clinical outcomes in ART-na€ ıve patients [21] [22] [23] [24] . Therefore, we believe that these results should be interpreted with caution. In treatment-experienced patients, DRV/r and ATZ/r have been shown to be suitable for switching strategies with suppressed VL [25] [26] [27] [28] , while DRV/r has been demonstrated to be the most effective PI/r in ART salvage strategies [7, 29, 30] . Regarding LPV/r, its posology, as well as a worse tolerance profile compared with DRV/r and ATZ/r [5, 6] , currently makes it difficult to use in switching strategies. Nevertheless, LPV/r continues to have a role in second-line regimens in resource-limited settings [1] . Consistently, our results show a lower risk of experiencing VF and treatment discontinuation for any reason or because of toxicity in patients starting DRV/r compared with those initiating ATZ/r or LPV/r, reflecting the well-known better efficacy and safety profile of DRV/r and of ATZ/r compared with LPV/r-based regimens [5] [6] [7] . However, confounding by indication for switching cannot be ruled out.
As expected, the availability of genotyping tests and the number of prior failures of treatment with non-PI-and PI-based ART were identified as predictors of virological response in patients from both treatmentexperienced subgroups. Having a history of genotypic testing might be considered a proxy of poor adherence or reflect selected testing for people perceived to be at increased risk of detection of resistance and risk of failure. Other characteristics such as older age, female gender, men who have sex with women, black ethnicity, and coinfection with HCV were also identified in our study as factors associated with increased risks of VF and treatment discontinuation in the ART-experienced patients. Similar results have been previously reported [23, [31] [32] [33] [34] [35] [36] [37] [38] , and may be attributable to confounding as a consequence of differences in sociodemographic characteristics [34] .
Our analysis has a number of limitations. First, we cannot rule out confounding by indication and calendar year as our patients were not randomized to the evaluated strategies. One crucial unmeasured possible confounder is indeed ART adherence, which has been shown to guide treatment choices and to be a predictor of treatment response and survival in HIV-infected patients [39, 40] . Moreover, the better tolerance profile as well as the oncedaily dosage could have favoured better adherence to DRV/r and ATV/r regimens compared with LPV/r regimens [5, 6] . Secondly, participants were from multiple countries showing a great diversity of socioeconomic and demographic characteristics, as well as differences in access to care, medical insurance, prevalence of immigration, comorbidities and incidence of mental health disorders in people who inject drugs (PWID) patients, pharmacokinetic or pharmacodynamic factors, and composition of the ART, some of which we tried to control for in the analysis, but residual confounding is still possible. These limitations, however, are inherent to the design of a continent-wide multicentre observational study subject to different local guidelines for the management of chronic HIV infection. Nevertheless, results from the multivariable Cox proportional hazard model were adjusted by clinical site.
The key strengths of our study are the inclusion of an unselected population of HIV-infected individuals routinely seen for care across Europe and the fact that we show robust estimates of the rates of treatment failure up to 5 years after the date of initiation. Our results suggest that, in routine clinical practice, DRV/r-based regimens are independently associated with less risk of experiencing VF and any discontinuation or toxicity, showing higher longterm effectiveness than those of ATZ/r-and LPV/r-based regimens, especially in ART-experienced patients. Findings from this study may be reasonably extrapolated to people living with HIV infection in European and other developed countries. Moreover, from the point of view of the new 90-90-90 WHO targets, our findings suggest that DRV/ r-containing regimens may be considered a preferred PI/r option relative to other PI/rs. DRV/r, however, is the most expensive PI currently available. Therefore, policies to reduce the cost of DRV/r and improve its accessibility in developing countries are still necessary.
In summary, assuming no unmeasured confounding factors, the long-term effectiveness of boosted PI-containing regimens in ART-experienced subjects appears to be greater in people receiving DRV/r than in those receiving ATZ/r and LPV/r. The same tendency was observed in ART-na€ ıve patients, although the analysis was likely to be underpowered in this population. Strategies to improve clinical care and treatment response continue to be necessary in some subsets of the HIV-infected population such as women, injecting drug users, hepatitis virus-coinfected patients and ethnic minorities.
Acknowledgements
We are grateful to Michael Kennedy-Scanlon for editorial assistance.
Conflicts of interest
JRS has received research funding, consultancy fees, and lecture sponsorships from and has served on advisory boards for Abbvie, Boehringer Ingelheim, Gilead Sciences, Janssen-Cilag, Bristol-Myers Squibb, Merck Sharp & Dohme, and ViiV Healthcare. PR through his institution has received independent scientific grant support from Gilead Sciences, Janssen Pharmaceuticals Inc., Merck & Co, Bristol-Myers Squibb and ViiV Healthcare; he has served on a scientific advisory board for Gilead Sciences and a data safety monitoring committee for Janssen Pharmaceuticals Inc.; he chaired a scientific symposium by ViiV Healthcare, for which his institution has received remuneration. CP has received research funding from Gilead Sciences through his institution. JB has received consultancy fees and lecture sponsorships from and has served on advisory boards for Abbvie, Gilead Sciences, Janssen-Cilag, Bristol-Myers Squibb, Merck Sharp & Dohme, Hexal and ViiV Healthcare. AL has received consultancy fees and lecture sponsorships from and has served on advisory boards for Abbvie, Gilead Sciences, Janssen-Cilag, Bristol-Myers Squibb, Merck Sharp & Dohme, and ViiV Healthcare. PGK has received lecture fees and honoraria from Astellas, ViiV Healthcare, Gilead Sciences, Janssen-Cilag and Merck Sharp & Dohme. CD has received travel grants, honoraria or study grants from Abbvie, Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme and ViiV Healthcare. RP has received research funding and consultancy fees from and has served on advisory boards for Boehringer-Ingelheim, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme, Pfizer, and ViiV Healthcare. All other authors declare no conflicts of interest. 
Supporting Information
Additional Supporting Information may be found in the online version of this article at the publisher's web-site: Fig. S4 . Predictor factors of virological response in patients initiating DRV/r-, ATZ/r-, and LPV/r-based treatments in patients from ART-switching subgroup. Fig. S5 . Predictor factors of virological response in patients initiating DRV/r-, ATZ/r-, and LPV/r-based treatments in patients with VL >500 copies/mL and genotyping test available at baseline. 
